MDR1 (multidrug resistence 1) can regulate GCS (glucosylceramide synthase) in breast cancer cells
Authors:
- 2 May 2011
- journal article
- research article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 104 (5) , 466-471
Abstract
Background and Objectives: Besides MDR1/P‐glycoprotein (MDR1/P‐gp), glucosylceramide synthase (GCS), an enzyme, which transfers UDP–glucose to ceramide to form glucosylceramide was also related with multidrug resistance (MDR) in breast cancer. Although many research showed that GCS could affect mdr1 in cancer cells, nobody knows that whether mdr1 can affect GCS in breast cancer. Our study aims to verify that.Methods: A plasmid with multidrug resistence 1(mdr1) cDNA was transfected into the sensitive breast cancer cell line MCF‐7, while an RNA interference (RNAi) vector targeted mdr1 was transfected into the MDR cell line MCF‐7/ADM. Then RT‐PCR, Western blot, MTT, and flow cytometry were used to assess the expression and function of mdr1 and GCS.Result: The data displayed that up‐regulation of mdr1 could increase the expression of GCS, while the RNAi‐expression plasmids could decrease that. Meantime, the changes of ceramide are opposed to that of GCS and are the same to the alteration of apoptosis rate.Conclusions: Our results demonstrate that MDR1 could increase cellular apoptosis by regulating the expression of GCS in breast cancer cells. J. Surg. Oncol. 2011; 104:466–471.Keywords
Funding Information
- National Natural Science Foundation of China (30972929)
- Independent Innovation Foundation of Shandong University
This publication has 22 references indexed in Scilit:
- Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and β-catenin signalingMolecular Cancer, 2010
- Targeting glucosylceramide synthase downregulates expression of the multidrug resistance gene MDR1 and sensitizes breast carcinoma cells to anticancer drugsBreast Cancer Research and Treatment, 2009
- Reversal of drug resistance in breast carcinoma cells by anti-mdr1 ribozyme regulated by the tumor-specific MUC-1 promoterCancer Letters, 2007
- A case study in misidentification of cancer cell lines: MCF-7/AdrR cells (re-designated NCI/ADR-RES) are derived from OVCAR-8 human ovarian carcinoma cellsCancer Letters, 2007
- MRP1 and glucosylceramide are coordinately over expressed and enriched in rafts during multidrug resistance acquisition in colon cancer cellsInternational Journal of Cancer, 2004
- Altered sphingolipid metabolism in multidrug‐resistant ovarian cancer cells is due to uncoupling of glycolipid biosynthesis in the Golgi apparatusThe FASEB Journal, 2002
- Ceramide glycosylation potentiates cellular multidrug resistanceThe FASEB Journal, 2001
- Agents that Reverse Multidrug Resistance, Tamoxifen, Verapamil, and Cyclosporin A, Block Glycosphingolipid Metabolism by Inhibiting Ceramide Glycosylation in Human Cancer CellsJournal of Biological Chemistry, 1997
- Accumulation of Glucosylceramides in Multidrug-resistant Cancer CellsJournal of Biological Chemistry, 1996
- Induction of glucosylceramide synthase by synthase inhibitors and ceramideBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1996